ABSTRACT: A quasi-equilibrium mass transport analysis has been developed to quantitatively explain the solubility-permeability interplay that exists when using cyclodextrins as pharmaceutical solubilizers. The model considers the effects of cyclodextrins on the membrane permeability ( P m ) as well as the unstirred water layer (UWL) permeability ( P aq ), to predict the overall effective permeability ( P eff ) dependence on cyclodextrin concentration (C CD ). The analysis reveals that: (1) UWL permeability markedly increases with increasing C CD since the effective UWL thickness quickly decreases with increasing C CD ; (2) membrane permeability decreases with increasing C CD , as a result of the decrease in the free fraction of drug; and (3) since P aq increases and P m decreases with increasing C CD , the UWL is effectively eliminated and the overall P eff tends toward membrane control, that is, P eff % P m above a critical C CD . Application of this transport model enabled excellent quantitative prediction of progesterone P eff as a function of HPbCD concentrations in PAMPA assay, Caco-2 transepithelial studies, and in situ rat jejunal-perfusion model. This work demonstrates that when using cyclodextrins as pharmaceutical solubilizers, a trade-off exists between solubility increase and permeability decrease that must not be overlooked; the transport model presented here can aid in striking the appropriate solubility-permeability balance in order to achieve optimal overall absorption.
INTRODUCTION
Modern drug discovery techniques (e.g., advances in high throughput screening methods, the introduction of combinatorial chemistry) have resulted in an increase in the number of drug candidates being selected that exhibit low solubility in water. By some estimates, more than 40% of new drug candidates are lipophilic and have poor aqueous solubility. [1] [2] [3] With very minor exceptions, dissolution of the drug substance in the aqueous gastrointestinal (GI) milieu is a prerequisite for absorption following oral administration. Hence, compounds with inadequate aqueous solubility often suffer from limited oral bioavailability. A great challenge facing the pharmaceutical scientist is to formulate these molecules into orally administered dosage forms with sufficient bioavailability. 4, 5 Among the various approaches to improve the aqueous solubility of lipophilic drugs, the utilization of cyclodextrins has become widespread in recent years. 6, 7 Cyclodextrins are crystalline, nonhygroscopic, cyclic oligosaccharides, with a hydrophilic outer surface and a less hydrophilic central cavity which is able to host hydrophobic solutes. From a drug delivery standpoint, cyclodextrins have gained extensive attention and use, due to their ability to increase the solubility of hydrophobic drugs via the formation of more water soluble inclusion complexes. 8, 9 According to the Biopharmaceutics Classification System (BCS), 10 the extent of oral absorption of a drug is governed by two primary factors: (1) the effective permeability across the intestinal mucosa and (2) the solubility and dissolution characteristics in the GI milieu. [11] [12] [13] While increased solubility of a lipophilic drug can be achieved by a cyclodextrins based delivery system, the effect of such a formulation on the apparent permeability is not completely understood. Several studies have shown that the use of cyclodextrins can reduce the apparent permeability of the drug, [14] [15] [16] an effect that is often qualitatively attributed to a decrease in the free fraction of the drug available for membrane permeation. These opposing effects of cyclodextrins on solubility and permeability can lead to paradoxical effects on the overall fraction of drug absorbed. Indeed, a critical review of the literature reveals that the use of cyclodextrins can result in enhanced, unchanged, or even decreased oral bioavailability. 17, 18 As a result of these observations, qualitative guidelines for the proper use of cyclodextrins have been proposed, 14, 18, 19 however no quantitative analysis that enables simulation of the overall effect of cyclodextrins on intestinal membrane permeability is currently available.
The aims of this research were to develop mathematical mass transport models to explain the impact of molecular complexation with cyclodextrins on intestinal membrane permeation, and to mechanistically elucidate the interplay between the opposing effects of cyclodextrins on apparent solubility and permeability. To evaluate the mathematical theory, the models were applied to the highly lipophilic, lowsolubility, BCS class II drug progesterone, 20 utilizing several in vitro and in situ intestinal membrane transport models, that is, PAMPA, Caco-2 cell monolayers, and single-pass rat jejunal perfusion. Overall, this work provides an increased understanding of the underlying mechanisms that govern the effects of molecular complexation on intestinal membrane transport, and enables the more efficient and intelligent use of molecular complexation strategies to facilitate oral absorption.
THEORY Quasi-Equilibrium Analysis of the Effect of Cyclodextrins on Membrane Transport
The intrinsic membrane permeability of free drug ( P m( F) ) in the absence of cyclodextrins can be written as: 21 P mðFÞ ¼ D mðFÞ K mðFÞ h mðFÞ (1) where D m( F) is the membrane diffusion coefficient of the free drug in the absence of cyclodextrins, K m( F) the membrane/aqueous partition coefficient of drug in the absence of cyclodextrins, and h m( F) the membrane thickness experienced by free drug in the absence of cyclodextrins.
Likewise, the apparent membrane permeability of the drug in the presence of cyclodextrins ( P m ) can be written as:
where D m is the apparent membrane diffusion coefficient of the drug in the presence of cyclodextrins and K m is the apparent membrane/aqueous partition coefficient of the drug in the presence of cyclodextrins.
Assuming only the free drug permeates the membrane such that D m( F) ¼ D m and that the presence of cyclodextrins does not effect the membrane thickness such that h m( F) ¼ h m , Eqs. (1) and (2) can be combined to give:
K m( F) and K m can be expressed as:
where S m( F) is the membrane solubility of the free drug, S aq( F) the aqueous solubility of the free drug, S m the apparent membrane solubility of the drug in the presence of cyclodextrins, and S aq the apparent aqueous solubility of the drug in the presence of cyclodextrins.
Assuming that the presence of cyclodextrins does not affect the drug solubility in the membrane such that S m( F) ¼ S m , Eqs. (3)-(5) can be combined to give:
Assuming 1:1 complexation between drug and cyclodextrins, the dependence of drug solubility on cyclodextrins concentration (C CD ) can be written as:
where K 11aq is the aqueous association constant of the 1:1 drug/cyclodextrins complex. Eqs. (6) and (7) can be combined to express the P m dependence on C CD :
Recognizing that the fraction of free drug ( F) can be written as:
Eqs. (8) and (9) can be combined to express the P m dependence on F:
The intrinsic permeability of the free drug through the unstirred aqueous boundary layer ( P aq( F) ) in the absence of cyclodextrins can be written as: 22 P aqðFÞ ¼ D aqðFÞ h aqðFÞ (11) where D aq( F) is the diffusion coefficient of the free drug through the unstirred aqueous boundary layer in the absence of cyclodextrins and h aq( F) is the unstirred aqueous boundary layer thickness experienced by free drug in the absence of cyclodextrins. Likewise, the apparent unstirred aqueous boundary layer permeability of the drug in the presence of cyclodextrins ( P aq ) can be written as:
where D aq is the apparent diffusion coefficient of the drug through the unstirred aqueous boundary layer in the presence of cyclodextrins and h aq is the apparent unstirred aqueous boundary layer thickness in the presence of cyclodextrins. Eqs. (11) and (12) can be combined to give: (16) where h aq(B) is the apparent unstirred aqueous boundary layer thickness experienced by the drugcyclodextrin complex. Eqs. (11), (13), (14) , and (16) can be combined to show the dependence of P aq on both free and bound drug:
Assuming that the unstirred aqueous boundary layer is no longer relevant for the drug-cyclodextrin complex (i.e., h aq(B) ¼ 0 and h aq ¼ Fh aq( F) ), Eqs. (9) and (17) can be combined to express the P aq dependence on C CD :
where the dependence of D aq on C CD may be calculated using Eqs. (14) and (15) . Taking into account the membrane permeability as well as the unstirred aqueous boundary layer permeability on either side of the membrane, P aq (1) and P aq (2) , the overall effective permeability ( P eff ) of the drug can be written as:
For simplicity, P aq (2) is assumed to have a negligible effect, such that P aq(1) ¼ P aq , and Eq. (19) can be rewritten as:
Thus, the overall P eff dependence on C CD may be predicted via Eq. (20) wherein the P m and P aq dependence on C CD are predicted using Eqs. (8) and (18) with knowledge of P m( F) , K 11aq , P aq( F) , D aq( F) , and D aq(CD) .
Moreover, the drug concentration at the interface between the UWL and membrane (C aq Membrane Surface ) as a function of C CD can be calculated according to the following equation:
The assumptions nested in these analyses include: (1) quasi-equilibrium conditions (2) 1:1 stoichiometry between drug/cyclodextrin complex; (3) only the free drug partitions and diffuses into the membrane, but not the drug/cyclodextrin complex, such that S m( F) ¼ S m and D m( F) ¼ D m ; (4) the presence of cyclodextrins does not affect the membrane thickness such that h m( F) ¼ h m ; and (5) only the free drug encounters a significant unstirred aqueous boundary layer thickness but the unstirred aqueous boundary layer thickness is negligible for the drugcyclodextrins complex such that h aq(B) ¼ 0.
MATERIALS AND METHODS

Materials
Progesterone, 2-hydroxypropyl-b-cyclodextrins (HPb-CD), phenol red and hexadecane were purchased from Sigma Chemical Co. (St. Louis, MO). Hexane, potassium chloride, and NaCl were obtained from Fisher Scientific, Inc. (Pittsburgh, PA). Acetonitrile and water (Acros Organics, Geel, Belgium) were HPLC grade. All other chemicals were of analytical reagent grade.
Solubility Studies
The solubility experiments for progesterone with HPbCD were conducted according to the method described by Higuchi and Connors. 23 To a number of test tubes containing excess amounts of progesterone, 0-0.015 M aqueous HPbCD solutions were added. The intrinsic solubility in water was determined from five individual samples without HPbCD. The test tubes were tightly closed and placed in a shaking water bath at 258C and 100 rpm. Establishment of equilibrium was assured by comparison of samples after 24 and 48 h. Before sampling, the vials were centrifuged at 10,000 rpm for 10 min. Supernatant was carefully withdrawn from each test tube, filtered, and immediately assayed for drug content by HPLC.
Caco-2 Cell Monolayer Assay
Caco-2 cells (passage 25-32) from American Type Culture Collection (Rockville, MD) were routinely maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen Corp., Carlsbad, CA) containing 10% fetal bovine serum, 1% nonessential amino acids, 1 mM sodium pyruvate, and 1% L-glutamine. Cells were grown in an atmosphere of 5% CO 2 and 90% relative humidity at 378C. The DMEM medium was routinely replaced by fresh medium every 3 days. Cells were passaged upon reaching approximately 80% confluence using 4 mL trypsin-EDTA (Invitrogen Corp.).
Transepithelial transport studies were performed using a method described previously. 24, 25 Briefly, 5 Â 10 4 cells/cm 2 were seeded onto collagen-coated membranes (12-well Transwell plate, 0.4-mm pore size, 12 mm diameter, Corning Costar, Cambridge, MA) and were allowed to grow for 21 days. Mannitol and Lucifer yellow permeabilities were assayed for each batch of Caco-2 monolayers (n ¼ 3), and TEER measurements were performed on all monolayers (Millicell-ERS epithelial Voltohmmeter, Millipore Co., Bedford, MA). Monolayers with apparent mannitol and Lucifer yellow permeability <3 Â 10 À7 cm/s, and TEER values >300 Vcm 2 were used for the study. On the day of the experiment, the DMEM was removed and the monolayers were rinsed and incubated for 20 min with a blank transport buffer. The apical transport buffer contained 1 mM CaCl 2 , 0.5 mM MgCl 2 Á6H 2 O, 145 mM NaCl, 3 mM KCl, 1 mM NaH 2 PO 4 , 5 mM D-glucose, and 5 mM MES, at pH 6. Following the 20 min incubation, the drug free transport buffer was removed from the apical side and replaced by 0.5 mL of progesterone solution in the uptake buffer, with or without HPbCD. Throughout the experiment, the transport plates were kept in a shaking incubator (50 rpm) at 378C (unless stated otherwise). Samples were taken from the receiver (basolateral) side at various time points up to 120 min (50 mL), and similar volumes of blank buffer were added following each sample withdrawal. At the last time point (120 min), sample was taken from the donor (apical) side as well, in order to confirm mass balance. Samples were immediately assayed for drug content. Caco-2 monolayers were checked for confluence by measuring the TEER before and after the transport study.
Permeability coefficient ( P app ) across Caco-2 cell monolayers was calculated from the linear plot of drug accumulated in the receiver side versus time, using the following equation:
where dQ/dt is the steady-state appearance rate of the drug on the receiver side, C 0 the initial concentration of the drug in the donor side, and A the monolayer growth surface area (1.12 cm 2 ). Linear regression was carried out to obtain the steady-state appearance rate of the drug on the receiver side.
Parallel Artificial Membrane Permeation Assay (PAMPA)
PAMPA studies were carried out using a method described previously with minor modifications. 26, 27 Solutions of progesterone (25 mM) were prepared with HPbCD at concentrations of 0, 0.1, 0.2, 0.4, 0.8, and 1.6 mM in phosphate buffer saline (PBS) pH 7.4. PAMPA experiments were carried out in Millipore (Danvers, MA) 96-well MultiScreen-Permeability filter plates with 0.3 cm 2 polycarbonate filter support (0.45 mm). The filter supports in each well were first impregnated with 15 mL of a 5% solution (v/v) of hexadecane in hexanes. The wells were then allowed to dry for 1 h to ensure complete evaporation of the hexanes resulting in a uniform layer of hexadecane. The donor wells were then loaded with 0.15 mL of the progesterone-HPbCD solution and each receiver well was loaded with 0.3 mL of PBS. Five wells were loaded at each HPbCD concentration to enable collection of a well at times points of 30, 60, 90, 120, and 150 min and each experiment was repeated three times for a total of 15 wells per HPbCD concentration. The donor plate was then placed upon the 96-well receiver plate and the resulting PAMPA sandwich was incubated at 258C. Receiver plate wells (n ¼ 3 for each HPbCD concentration) were then collected every 30 min over 2.5 h and the progesterone concentration in each well was determined by HPLC. Permeability coefficient ( P app ) across Caco-2 cell monolayers was calculated from the linear plot of drug accumulated in the receiver side versus time using Eq. (22) .
Rat Jejunal Perfusion
All animal experiments were conducted using protocols approved by the University Committee of Use and Care of Animals (UCUCA), University of Michigan, and the animals were housed and handled according to the University of Michigan Unit for Laboratory Animal Medicine guidelines. Male albino Wistar rats (Charles River, IN) weighing 250-300 g were used for all perfusion studies. Prior to each experiment, the rats were fasted overnight (12-18 h) with free access to water. Animals were randomly assigned to the different experimental groups.
The procedure for the in situ single-pass intestinal perfusion followed previously published reports. 28, 29 Briefly, rats were anesthetized with an intramuscular injection of 1 mL/kg of ketamine-xylazine solution (9%:1%, respectively) and placed on a heated surface maintained at 378C (Harvard Apparatus Inc., Holliston, MA). The abdomen was opened by a midline incision of 3-4 cm. A 10 cm proximal jejunal segment was carefully exposed and cannulated on two ends with flexible PVC tubing (2.29 mm i.d., inlet tube 40 cm, outlet tube 20 cm, Fisher Scientific, Inc.). Care was taken to avoid disturbance of the circulatory system, and the exposed segment was kept moist with 378C normal saline solution. Solutions of progesterone (25 mM) were prepared with HPbCD at concentrations of 0, 0.025, 0.25, and 2.5 mM in the perfusate buffer. This buffer consisted of 10 mM MES buffer, pH 6.5, 135 mM NaCl, 5 mM KCl, and 0.1 mg/mL phenol red, a nonabsorbable marker for measuring water flux. All perfusate solutions were incubated in a 378C water bath. The isolated segment was first rinsed with blank perfusion buffer at a flow rate of 0.5 mL/ min to clean out any residual debris. At the start of the study, the test solutions were perfused through the intestinal segment (Watson Marlow Pumps 323S, Watson-Marlow Bredel, Inc., Wilmington, MA) at a flow rate of 0.2 mL/min. The perfusion buffer was first perfused for 1 h, in order to ensure steady state conditions (as also assessed by the inlet over outlet concentration ratio of phenol red which approaches 1 at steady state). After reaching steady state, samples were taken in 10 min intervals for 1 h. All samples, including perfusion samples at different time points, original drug solution, and inlet solution taken at the exit of the syringe were immediately assayed by HPLC. Following the termination of the experiment, the length of each perfused jejunal segment was accurately measured.
The net water flux in the single-pass rat jejunal perfusion studies, resulting from water absorption in the intestinal segment, was determined by measurement of phenol red, a nonabsorbed, nonmetabolized marker. The measured C out /C in ratio was corrected for water transport according to the following equation: (23) where C in phenol red is the concentration of phenol red in the inlet sample, and C out phenol red is the concentration of phenol red in the outlet sample. The effective permeability ( P eff ) through the rat gut wall in the single-pass intestinal perfusion studies was determined assuming the ''plug flow'' model expressed in the following equation:
where Q is the perfusion buffer flow rate, C 0 out /C 0 in is the ratio of the outlet concentration and the inlet concentration of the tested drug that has been adjusted for water transport via Eq. (23), R is the radius of the intestinal segment (set to 0.2 cm), and L is the length of the intestinal segment.
High-Performance Liquid Chromatography (HPLC)
HPLC analyses were performed on an Agilent Technologies (Palo Alto, CA) HPLC 1100 equipped with photodiode array detector and ChemStation for LC 3D software. Progesterone was assayed using an Agilent Technologies 150 mm Â 4.6 mm XDB-C 18 column with 5 mm particle size. The detection wavelength was 242 nm. The mobile phase consisted of 30:70 (v/v) 0.1% trifluoroacetic acid in water: 0.1% trifluoroacetic acid in acetonitrile and was pumped at a flow rate of 1.0 mL/min. Injection volumes for all HPLC analyses ranged from 5 to 100 mL. Separate standard curves were used for each experiment (R 2 > 0.99).
Statistical Analysis
All in vitro experiments were performed in triplicate (unless stated otherwise), and all animal experiments were n ¼ 4. Values are expressed as the means AE the standard deviation (SD). To determine statistically significant differences among the experimental groups, the nonparametric Kruskal-Wallis test was used for multiple comparisons, and the two-tailed nonparametric Mann-Whitney U-test for two-group comparison where appropriate. A p-value of less than 0.05 was termed significant.
RESULTS
Effect of HPbCD on Progesterone Solubility
The solubility data for complex formation between progesterone and HPbCD is presented in Figure 1 . Progesterone solubility increased linearly (R 2 > 0.99) with increasing HPbCD concentrations as per Eq. (7).
The linearity of the phase solubility diagram indicates 1:1 stoichiometric complexation between progesterone and HPbCD. A very strong binding constant of 14,324 M À1 was calculated from the solubility data via Eq. (7).
Effect of HPbCD on Progesterone Transport Across Caco-2 Cell Monolayers
The dependence of progesterone flux across Caco-2 cell monolayer, and the corresponding P app values, on HPbCD concentration (0 and 75 mM) is presented in Figure 2 . It can be seen that progesterone permeability decreased twofold in the presence of 75 mM HPbCD as compared to progesterone alone. These data were obtained under a constant rotation speed of 50 rpm. To determine whether the results obtained under this condition represent the true membrane permeability ( P m( F) ) of progesterone, that is, to assess the effect of the unstirred water layer (UWL), progesterone Caco-2 permeability was evaluated as a function of rotation speed (Fig. 3a) . Significantly higher transport was evident with increased rotation speed from 0, to 20, and to 50 rpm, indicating that progesterone P app is limited by the UWL, at low rotation speeds. Additional increase in rotation speed to 70 rpm failed to produce increased flux, indicating that the UWL does not limit the overall P app at high rotation speeds. Hence, it is evident that the P app value obtained at 50 rpm (4.8 Â 10 À5 cm/s) approximates the true intrinsic membrane permeability ( P m( F) ) of progesterone across Caco-2 monolayers.
The effect of rotation speed on progesterone Caco-2 membrane transport was also evaluated in the presence of 75 mM HPbCD. As shown in Figure 3b , similar progesterone permeabilities were obtained at different rotation speeds 0-50 rpm, consistent with the idea that the UWL is no longer rate limiting and progesterone P app is under membrane control at an HPbCD concentration as low as 75 mM. This observation is in corroboration with previous reports that cyclodextrins may reduce the UWL effect on the P app of lipophilic compounds. 
À6 cm 2 /s from Amidon et al., 22 and
À6 cm 2 /s from Ribeiro et al. 33 The value of P aq( F) was calculated to be 10.6 Â 10 À5 cm/s via Eq. (20) using the experimental P app value of 3.3 Â 10 À5 cm/s at 0 rpm rotation speed in the absence of cyclodextrins for P eff , and the experimental P app value of 4.8 Â 10 À5 cm/s at 50 rpm rotation speed in the absence of cyclodextrins for P m( F) . The predicted values for both P eff and P m agreed well with the experimentally observed P app value of 2.3 Â 10 À5 cm/s at a cyclodextrins concentration of 75 mM (Fig. 4) . In fact, the theoretical value of P m calculated via Eq. (8) exactly matched the experimentally observed P app value.
Effect of HPbCD on Progesterone Transport in PAMPA Model
The theoretical and experimental dependence of progesterone P app on HPbCD concentration in the hexadecane-based PAMPA model is shown in Figure 5 . Progesterone PAMPA permeability in the absence of HPbCD was investigated at increasing rotation speeds as well, in order to assess the effect of the UWL (Fig. 6 ). Progesterone permeability decreased 2.1, 3.5, 6.4, 15.4, and 33.1 times at HPbCD concentrations of 0.1, 0.2, 0.4, 0.8, and 1.6 mM, respectively, as compared to progesterone alone (Fig. 5) . It can be seen that progesterone permeability in the PAMPA model remained constant with increasing rotation speed up to 100 rpm (Fig. 6 ). This indicates that progesterone permeability is under membrane control in the hexadecane membrane PAMPA model. Thus, the effect of the UWL does not need to be considered and Eq. (8) may be directly applied to predict the dependence of progesterone apparent membrane permeability on HPbCD concentration. Hence, the theoretical progesterone PAMPA permeability as a function of HPbCD concentration illustrated in Figure 5 was calculated via Eq. (8) (Fig. 5) .
Effect of HPbCD on Progesterone Rat Jejunal Permeability
The theoretical and experimental progesterone permeability in the single-pass intestinal-perfusion rat model with increasing HPbCD concentrations (0, 0.025, 0.25, and 2.5 mM) is illustrated in Figure 7 . In the absence of HPbCD, progesterone showed very high permeability (82.4 Â 10 À5 cm/s) across rat jejunum. The addition of an equi-molar (25 mM) amount of HPbCD resulted in no significant increase in P eff (84.8 Â 10 À5 cm/s). However, the P eff of progesterone decreased 1.8-fold in the presence of 0.25 mM HPbCD and 7.8-fold in the presence of 2.5 mM HPbCD. The predicted lines for P m , P aq , and P eff in Figure 7 were calculated via Eqs. (8), (18) and (20) 33 The experimental value for progesterone rat jejunal P m( F) of 250 Â 10 À5 cm/s used in the calculations was previously estimated by determining the P eff of progesterone at increasing perfusate flow rates. 34 The value of P aq( F) used in the predictions was calculated according to Eq. (20) from the experimental values of P m(F) and the P eff of progesterone determined in the absence of cyclodextrins (82.4 Â 10 À5 cm/s). Excellent agreement was obtained between the experimental and predicted progesterone P eff values at all of the HPbCD concentrations tested. Figure 8 contains the predicted D aq , h aq , and P aq as a function of HPbCD concentration for progesterone in the rat jejunal perfusion model. The theoretical curves were calculated according to Eqs. (14)- (18) . The value of h aq( F) was calculated to be 103 mm via Eq. (12) using the P eff of progesterone determined in the absence of cyclodextrins (82.4 Â 10 À5 cm/s) and the progesterone D aq( F) ¼ 8.5 Â 10 À6 cm 2 /s from Amidon et al.
22 Figure 9 shows the theoretical membrane surface to bulk concentration ratio (C aq Membrane Surface /C aq Bulk ) of progesterone as a function of HPbCD concentration in the rat jejunal perfusion model. The predicted curve was calculated via Eq. (21) . Figure 10 illustrates the effect of HPbCD on progesterone aqueous solubility and permeability based on the theoretical quasi-equilibrium transport analysis developed in this work. The apparent solubility and permeability as a function of HPbCD concentration curves were calculated using Eqs. (7) and (20), respectively.
DISCUSSION
The trade-off between the apparent solubility increase and permeability decrease when using cyclodextrins as pharmaceutical solubilizers is described in this article. These opposing effects of cyclodextrin can lead to paradoxical effects on the overall fraction of drug absorbed. In this work, we offer a quantitative modeling of the interplay between the opposing effects of cyclodextrins on the apparent solubility and permeability, and show the excellent prediction of overall fraction of drug absorbed as a function of C CD obtained by the model.
The very strong molecular complexation between progesterone and HPbCD, as evidenced by the extremely high binding constant of 14,324 M À1 , results in substantially enhanced aqueous solubility (Fig. 1) . Indeed, this solubility advantage provided by cyclodextrins is the primary reason for their widespread popularity and use. The high binding constant also results in very little free progesterone, even at relatively low HPbCD concentrations. For example, the free fraction of progesterone is 0.5 at an HPbCD concentration of only 70 mM, and at HPbCD concentrations of >1.4 mM, the free fraction of progesterone is <0.05. This decreased fraction of free drug can significantly alter membrane permeation behavior as was observed in this work using the PAMPA, Caco-2 cell monolayers, and in situ rat jejunal perfusion models.
In the Caco-2 studies, progesterone permeability decreased twofold in the presence of 75 mM HPbCD (Figs. 2 and 3) , as compared to progesterone alone. In the absence of cyclodextrin, significantly higher permeabilities were observed with increased rotation speed from 0, to 20, and to 50 rpm, indicating that progesterone P app is limited by the UWL at low rotation speeds (Fig. 3a) . This observation is in corroboration with previous reports. 22, [34] [35] [36] An additional increase in rotation speed to 70 rpm failed to produce increased flux, indicating that in this experimental method, the UWL does not limit the overall P app at rotation speeds of 50 rpm and above (Fig. 3a) . Hence, it is evident that the P app value obtained at 50 rpm (4.8 Â 10 À5 cm/s) approximates the true membrane permeability ( P m(F) ) of progesterone across Caco-2 monolayers. In the presence of cyclodextrins, progesterone permeability was no longer limited by the UWL, as evidenced by the lack of rotation speed effect (Fig. 3b) . This is in agreement with previous reports showing that cyclodextrins may reduce the UWL effect on the P app of lipophilic compounds. 8, 16, 31, 32 Since progesterone Caco-2 permeability is under membrane control at an HPbCD concentration as low as 75 mM and 50 rpm stir speed, it follows that the predicted P m (Eq. 8) exactly matches the experimentally observed P app value at 75 mM HPbCD (Fig. 4) .
Progesterone permeability was also significantly impacted by the presence of HPbCD in the hexadecane-based PAMPA model (Fig. 5) . The overall transport was unaffected by rotation speed (Fig. 6 ), indicating that in this experimental model progesterone permeability is not significantly effected by the UWL, rather the rate of transport across the hexadecane membrane is rate limiting. This is not to say that the UWL is not present in the PAMPA model, rather the effect of the UWL on overall permeability is insignificant as compared to the hexadecane membrane. Hence, the P app in the absence of HPbCD can be assumed to be approximately equal to P m(F) and only the effect of HPbCD on Figure 10 . The effect of HPbCD on progesterone solubility (gray) and permeability (black) based on the theoretical quasi-equilibrium transport analysis. Solubility and permeability were calculated using Eqs. (7) and (20), respectively. P m (Eq. 8) needs to be considered (i.e., P eff % P m ). Indeed, excellent agreement was achieved between the experimental and predicted permeability of progesterone as a function of HPbCD concentration in the PAMPA model when Eq. (8) was used for the predictions (Fig. 5) .
Progesterone permeability across rat jejunal segments was also significantly altered by the presence of cyclodextrins. As shown in Figure 7 , the progesterone P eff across the rat jejunum stayed relatively consistent at very low HPbCD concentrations (0.025 mM), but then decreased rapidly with increasing cyclodextrins concentration (0.25-2.5 mM). This results because at very low cyclodextrins concentrations, the overall P eff is limited by the UWL. This is in corroboration with previous reports that have shown progesterone permeability to be limited by the aqueous boundary layer in the rat intestinal perfusion model. 34, 35 As shown in Figures 9 and 10, the predicted P aq increases markedly with increasing cyclodextrins concentration. This may be explained by the high value of K 11aq , as the UWL is only experienced by the free drug and is effectively eliminated for the progesterone-HPbCD complex (i.e., h aq(B) ¼ 0), such that the effective thickness of the boundary layer decreases with decreasing free fraction (i.e., h aq ¼ Fh aq( F) ). This is in agreement with and explains some previous reports showing that cyclodextrins may reduce the UWL effect on the apparent permeability of lipophilic compounds. 8, 16, 31, 32 Figure 8 shows the predicted D aq , h aq , and P aq dependence on HPbCD concentration, calculated via Eqs. (14)- (18) . The value of progesterone D aq decreases with increasing cyclodextrins concentration, which does contribute to a slight decrease in the overall value of P aq as expressed in Eqs. (12) and (18) . However, this effect is essentially negligible in comparison to the effect of the shrinking h aq , which leads to a marked increase in P aq with increasing HPbCD concentration (Fig. 8) . As shown in Figure 9 , the shrinking UWL with increasing HPbCD concentration also causes the progesterone concentration at the surface of the membrane to increase and eventually become equal to the progesterone concentration in the bulk as the concentration of HPbCD increases. In this way, complexation with cyclodextrins effectively shorts out the UWL by facilitating the transport of drug to the membrane surface such that C aq Membrane Surface % C aq Bulk , and permeation across the intestinal membrane becomes rate limiting. 22 At the same time, P m decreases rapidly with increasing cyclodextrin concentration (Fig. 7) . This may also be attributed to the high binding constant between progesterone and HPbCD, which causes the amount of free drug available for membrane permeation to decrease rapidly with increasing cyclodextrins concentration, as described in Eqs. (8) and (10) . Figure 7 contains the overall predicted P eff as a function of cyclodextrins concentration in the rat intestinal perfusion model. The predicted P eff was calculated via Eq. (20) . Excellent agreement was obtained between the experimental and predicted progesterone P eff values at all of the HPbCD concentrations tested. The overall P eff stays relatively constant at very low HPbCD concentrations, but then decreases rapidly with increasing cyclodextrin concentration. This results because at very low cyclodextrin concentrations, the overall P eff is limited by the UWL. However, the rapidly decreasing effective h aq with increasing HPbCD concentration causes P aq to markedly increase, such the UWL is quickly eliminated and the overall P eff becomes membrane controlled at higher HPbCD concentrations. This is evidenced by the fact that the experimental and predicted values of P eff are essentially equal to the predicted values of P m at the higher HPbCD concentrations of 0.25 and 2.5 mM (Fig. 7) . It is acknowledged that validation of any mathematical model is a continuous process, and additional data would be of benefit.
It should be emphasized that the shrinking effective h aq results directly from the decrease in free fraction of drug with increasing cyclodextrins concentration. Indeed, the UWL thickness experienced by the free drug remains constant with increasing cyclodextrins concentration. However, since the free fraction of drug decreases with increasing cyclodextrin concentration and it is assumed that the drug-cyclodextrin complex does not experience a UWL thickness (i.e., h aq(B) ¼ 0), the overall effective UWL thickness decreased as bound fraction increases and free fraction decreases (i.e., h aq ¼ Fh aq( F) ). As stated in the model assumptions, this model does not consider cases in which interaction between the free cyclodextrin and the membrane exists.
CONCLUSIONS
In conclusion, this work demonstrates that when using cyclodextrins as pharmaceutical solubilizers, a trade-off exists between solubility increase and permeability decrease that governs the overall fraction of drug absorbed. Given these opposing effects, both apparent solubility and permeability considerations must be taken into account, to strike the appropriate balance in order to achieve optimal absorption from a cyclodextrin-based formulation. The quasi-equilibrium mass transport analysis developed in this work could successfully predict the P eff dependence on HPbCD concentration with knowledge of K 11aq , P m(F) , P aq( F) and the aqueous diffusion coefficients of the free drug and cyclodextrins, D aq( F) and D aq(CD) . Knowledge of the solubility-permeability interplay and the dependence of these parameters on cyclodextrin concentration enables the more efficient and intelligent use of cyclodextrins in oral drug product formulation development.
